WuXi AppTec Co. Ltd. acquired a new stake in Adagene Inc. (NASDAQ:ADAG - Free Report) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor acquired 4,225,696 shares of the company's stock, valued at approximately $8,162,000. Adagene accounts for about 21.2% of WuXi AppTec Co. Ltd.'s investment portfolio, making the stock its 3rd biggest position. WuXi AppTec Co. Ltd. owned about 9.64% of Adagene at the end of the most recent reporting period.
Adagene Stock Performance
Shares of Adagene stock traded down $0.06 during mid-day trading on Wednesday, hitting $2.19. The stock had a trading volume of 197,731 shares, compared to its average volume of 84,472. The firm has a 50-day moving average of $2.74 and a two-hundred day moving average of $2.45. The company has a debt-to-equity ratio of 0.19, a quick ratio of 3.61 and a current ratio of 3.61. Adagene Inc. has a 12-month low of $1.10 and a 12-month high of $4.38.
About Adagene
(
Free Report)
Adagene Inc, a clinical stage immunotherapy company, engages in the research, development, and production of monoclonal antibody drugs for cancers. The company's product candidates include ADG106, a human ligand-blocking agonistic anti- CD137 IgG4 monoclonal antibodies (mAbs) that is in Phase 1b/2 clinical trials for the treatment advanced solid tumors and non-Hodgkin's lymphoma; ADG126, a fully-human anti-CTLA-4 mAb that is in Phase 1 clinical trial for the treatment advanced/metastatic solid tumors; and ADG116, a human ligand-blocking anti-CTLA-4 mAb, which is in Phase I clinical trial for the treatment of advanced metastatic solid tumors.
Featured Stories
Want to see what other hedge funds are holding ADAG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Adagene Inc. (NASDAQ:ADAG - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Adagene, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Adagene wasn't on the list.
While Adagene currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Click the link below and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio.
Get This Free Report
